Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Search
Search results
New website aims to increase understanding of genetics
High quality information on genetic testing and counselling for families affected by inherited sight loss is now available in one place thanks to the launch of an innovative new website, Unlock Genetics.
A week in the life of a researcher
On a typical week in the stem cell lab there are many different experiments going on. Different people work on their individual projects, but we often collaborate to share ideas and help each other.
Meet a researcher: Hassina Zeriri
It’s not very often that we come across a researcher working on a project inspired by their own lived experience of a sight loss condition.
Research grant awards worth £870K announced
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Retina-on-a-chip: the tiny technology offering big hope for inherited sight loss
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
New nanoparticle gene therapy research provides hope for treating inherited sight loss
Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.
Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
e-Newsletter June 2026
Our monthly e-Newsletter featuring the latest updates from Retina UK.